A detailed history of Russell Investments Group, Ltd. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 238,098 shares of RXRX stock, worth $1.65 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
238,098
Previous 148,763 60.05%
Holding current value
$1.65 Million
Previous $1.12 Million 40.72%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$5.92 - $8.6 $528,863 - $768,281
89,335 Added 60.05%
238,098 $1.57 Million
Q2 2024

Aug 08, 2024

SELL
$7.35 - $10.05 $70,133 - $95,897
-9,542 Reduced 6.03%
148,763 $1.12 Million
Q1 2024

May 08, 2024

BUY
$9.13 - $15.52 $450,035 - $765,011
49,292 Added 45.22%
158,305 $1.58 Million
Q4 2023

Feb 05, 2024

SELL
$5.09 - $10.79 $111,409 - $236,171
-21,888 Reduced 16.72%
109,013 $1.07 Million
Q3 2023

Nov 13, 2023

BUY
$6.59 - $15.86 $366,404 - $881,816
55,600 Added 73.84%
130,901 $1 Million
Q2 2023

Aug 10, 2023

SELL
$4.56 - $9.94 $258,346 - $563,150
-56,655 Reduced 42.93%
75,301 $562,000
Q4 2022

Feb 08, 2023

SELL
$7.16 - $12.7 $22,317 - $39,585
-3,117 Reduced 2.31%
131,956 $1.02 Million
Q3 2022

Nov 04, 2022

BUY
$7.83 - $13.6 $51,176 - $88,889
6,536 Added 5.08%
135,073 $1.44 Million
Q2 2022

Jul 29, 2022

BUY
$5.04 - $9.26 $647,826 - $1.19 Million
128,537 New
128,537 $1.05 Million
Q1 2022

May 05, 2022

SELL
$6.16 - $18.03 $210,462 - $616,012
-34,166 Closed
0 $0
Q4 2021

Jan 21, 2022

BUY
$16.14 - $21.86 $42,496 - $57,557
2,633 Added 8.35%
34,166 $584,000
Q2 2021

Aug 04, 2021

BUY
$18.0 - $37.42 $567,594 - $1.18 Million
31,533 New
31,533 $1.15 Million

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.25B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.